$PCRX insider trading
Over the last 12 months, Pacira BioSciences insiders reported no purchases and 13 sales totaling $2.5M across SEC Form 4 filings. 92% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.5M 13 events
- Events · 12m
- 13 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 92% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | SLONIN JONATHANChief Medical Officer · O | ▼ Sale | 3,040 | $23.23 | $71K | -1.4% | plan |
| Jun 11, 2026 | RIKER LAURENSenior Vice President, Finance · O | ▼ Sale | 6,115 | $23.5 | $144K | -8.9% | plan |
| Jun 4, 2026 | WILLIAMS KRISTENChief Administrative Officer · O | ▼ Sale | 10,259 | $22.27 | $228K | -5.8% | plan |
| Apr 23, 2026 | Cross ShawnChief Financial Officer · O | ▼ Sale | 12,941 | $25.16 | $326K | -10.9% | plan |
| Apr 22, 2026 | Cross ShawnChief Financial Officer · O | ▼ Sale | 12,059 | $25.09 | $303K | -10.3% | plan · 3 tranches |
| Mar 17, 2026 | SLONIN JONATHANChief Medical Officer · O | ▼ Sale | 3,261 | $22.82 | $74K | -1.4% | plan |
| Mar 17, 2026 | Froimson MarkD | ▼ Sale | 500 | $21.81 | $11K | -2.4% | — |
| Feb 2, 2026 | RIKER LAURENSenior Vice President, Finance · O | ▼ Sale | 4,000 | $20.81 | $83K | -7.1% | plan |
| Feb 2, 2026 | WILLIAMS KRISTENChief Administrative Officer · O | ▼ Sale | 13,137 | $20.53 | $270K | -9.1% | plan |
| Jan 5, 2026 | RIKER LAURENSenior Vice President, Finance · O | ▼ Sale | 1,416 | $24.24 | $34K | -2.3% | plan |
| Dec 10, 2025 | Cross ShawnChief Financial Officer · O | ▼ Sale | 25,000 | $25.07 | $627K | -30.8% | plan · 2 tranches |
| Nov 17, 2025 | SLONIN JONATHANChief Medical Officer · O | ▼ Sale | 3,960 | $24.09 | $95K | -2.2% | plan |
| Nov 10, 2025 | Cross ShawnChief Financial Officer · O | ▼ Sale | 12,060 | $22.09 | $266K | -17.7% | plan |
| Sep 4, 2025 | Ceesay AbrahamD | ▼ Sale | 2,354 | $27.19 | $64K | -20.7% | plan |
| Aug 7, 2025 | BIGAL MARCELOD | ▼ Sale | 4,912 | $23.67 | $116K | -30.1% | — |
Every $PCRX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Pacira BioSciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PCRX feed.